In contrast, 60% of the ESR1-negative tumours (group B), which show the highest expression of NFκB2 and RELB, harboured missense mutations in BRCA1, which could produce aberrant proteins but conserving some activities such as the capacity to activate the NFκB machinery. This evidence concerns the gene ESR1 and neoplasm.